Telix Pharmaceuticals Ltd ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $803.8M+55.6% YoYTTM through 31 Dec 2025
Net Income -$7.1M-121.2% YoYTTM through 31 Dec 2025
Free Cash Flow -$43MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 53.0% |
| EBITDA Margin | 6.4% |
| Operating Margin | 3.7% |
| Net Margin | -0.9% |
Returns
-1.7%ROE
-0.6%ROA
-1.1%ROIC
Balance Sheet Health
Debt / Equity1.05x
Current Ratio1.43x
Net Debt$294.5M
Cash & Equivalents$141.9M
Quality Metrics
Piotroski F-Score1 / 9
FCF Margin-5.3%
Multi-Year Trend
RevenueFY2025: $803.8M
Diluted EPSFY2025: $-0.02
Dividend
No dividend
Capital Allocation
Capex Intensity3.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Precision Medicine | $621.9M | +22.0% | View detailsContinued growth driven by Illuccix dose volumes and the commercial launch of Gozellix in the U.S. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.